Prevalence of High Tumor Mutational Burden Among Pediatric Patients With Solid Tumors.

Wenjun Zhong¹, E J Dettman¹, Lei Zhang¹, Alexander Gozman¹, Roman Groisberg¹, Razvan Cristescu¹, Matthew J Marton¹, Saumya D Sisoudiya², Meagan Montesion², Karthikeyan Murugesan², Irene M Shui¹

¹MRL, Merck & Co., Inc., Rahway, New Jersey, USA.

²Foundation Medicine, Inc., Boston, Massachusetts, USA.

PubMed DOI

Abstract

High tumor mutational burden (TMB-H), defined as ≥10 non-driver somatic mutations per mega base of genome sequenced (mut/Mb), and high microsatellite instability (MSI-H), which can lead to TMB-H, are both associated with response to the immunotherapy pembrolizumab. Data from the KEYNOTE-158 study demonstrated that the association between TMB-H and response to pembrolizumab is independent of MSI-H…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.